Merck & Co’s Keytruda reigns supreme among immunotherapies ... making it the most frequent molecular alteration, and there are currently no effective targeted therapies directed against it ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...